|   | 
                  
                       | 
                      | 
                    
                        
                            
                                | 
                                  
                                 | 
                             
                             |  
                            
                                
                                    
                                        
  
    
	  | 
   
  
    
        
          |   | 
          
              
                | 
                    ´ÏÆ®·Î¸µ±¸¾Ë½ºÇÁ·¹ÀÌ(Èñ¼®ÇÑ´ÏÆ®·Î±Û¸®¼¼¸°¿ë¾×)14.4mL  Nitrolingual Spray  
                    
                 | 
               
              
                
                     Àü¹®ÀǾàǰ | ±Þ¿©  
                         |  
                    
                    	
                    
                 | 
               
              
                | 
					
                     
                     ¼öÀÔÀǾàǰ
	                
                  
				  
                 | 
               
              
              
              
              
              |   |  
              
                
                    
                        | 
                      ¾Ë¸²:  | 
                      µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. | 
                     
                    | 
               
            
              
                
                   
                   
                   
                   
		   
                 | 
               
              
                | 
                  
                  
                 | 
               
              | 
            | 
         
       
       | 
   
    |  
  
    | 
      
     | 
     
  |                   
                                        | 
                                             | 
                                         
                            
                                
                            
                            
                              
                                                        
                              
                                                
                            
 |   
    | 
      
     | 
 
 |  
    
   
    | 
       
        À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
        ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
        À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
        ·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
       
     | 
   
  
     | 
   
  
  
    
      
  
    
       |  
      
        
          
            
                | Çã°¡Á¤º¸ | 
             
           
         | 
       
       |  
      
  
    | Ç׸ñ | 
    ³»¿ë | 
   
  
  
  
  
   
    û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå  »óÇÑ±Ý¾× | 
    
      
      
        
        685800141  
	    
	    
            [º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸] 
          
        
        
        
          
          
            \11,368 ¿ø/14.4mL/º´(2024.07.01)(ÇöÀç¾à°¡)
            \11,372 ¿ø/14.4mL/º´(2022.01.01)(º¯°æÀü¾à°¡)
        
          
            
	 
  	   
  	   
       
      
       
       
     
      
      
     
      
    
    
    
      
     [»óº´ÄÚµåÁ¶È¸]
      
      [Áúº´ÄÚµåÁ¶È¸]
     
     | 
   
   
    | ºü¸¥Á¶È¸ | 
    
      
     |   
   
  
  
  
   
    | Á¦Ç°¼º»ó | 
    ¹«»ö ³»Áö ¾à°£ ³ë¶õ»öÀÇ ¹æÇ⼺ ³¿»õ¸¦ °¡Áø ¸¼Àº ¾×ÀÌ ÃæÀüµÈ ÆßÇÁ½Ä½ºÇÁ·¹À̸¦ ÀåÂøÇÑ Åõ¸í À¯¸®º´  [Á¦ÇüÁ¤º¸ È®ÀÎ] |   
   
  
  
  
  
  
   
    | Æ÷À塤À¯Åë´ÜÀ§ | 
    1º´/»óÀÚ[(13.2g(14.4mL)/ ½ºÇÁ·¹ÀÌ ÀåÂøº´)] | 
   
  
  
  
   
    | Æ÷À塤ÄÚµå´ÜÀ§ | 
    
        
        
            | ¾àǰ±Ô°Ý | 
            ´ÜÀ§ | 
            Æ÷ÀåÇüÅ | 
            ´ëÇ¥ÄÚµå | 
            Ç¥ÁØÄÚµå | 
            ºñ°í | 
	     
        
        
            | 14.4¹Ð¸®¸®ÅÍ | 
            1 °³ | 
            º´ | 
            8806858001402 | 
            8806858001419 | 
            25¡É ÀÌÇÏ º¸°ü | 
	     
        
         
     | 
   
      
  
  	
   
    | ÁÖ¼ººÐÄÚµå | 
    
      202637CSI  
      
	  [µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
     | 
   
  
  
  
 
  
  
    
  
  
  
  
  
  
  
  
  
  
 
  
  
  
 
  
  
  
  
  
  
   
    | Çã°¡»çÇ× ¿ø¹®Á¶È¸ | 
    
      
	    [Çã°¡»çÇ× ¿ø¹®Á¶È¸] 
     | 
   
  
  
  
  
     
  
  
  
   
    | È¿´ÉÈ¿°ú | 
    
    [ÀûÀÀÁõ º° °Ë»ö] 
      
    
     
	 
      °ü»óµ¿¸ÆÁúȯÀ¸·Î ÀÎÇÑ Çù½ÉÁõ ¹ßÀ۽à ÀÀ±ÞÄ¡·á ¹× Çù½ÉÁõ ¹ßÀÛ¿¹¹æ
      
     | 
   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
    
  
  
  
  
  
   
    | ¿ë¹ý¿ë·® | 
    
      * Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù. 
    
     
      
      
      [󹿾à¾î] 
      Çù½ÉÁõ ¹ßÀ۽à À̾àÀ» 1ȸ ¶Ç´Â 2ȸ Çô¹Ø ȤÀº ÇôÀ§¿¡ ºÐ»çÇÑ´Ù.(¹ëºê¸¦ ÇÑ ¹ø ´©¸£¸é ´ÏÆ®·Î±Û¸®¼¼¸° 0.4¹Ð¸®±×¶÷ÀÌ ºÐ¹«µÈ´Ù.) 
Áõ¼¼ ½ÃÀÛÈÄ 15ºÐ À̳»¿¡ 3ȸ ÀÌ»ó »ç¿ëÇÏÁö ¸» °Í. Çù½ÉÁõ À¯¹ßÀÌ ¿¹»óµÇ´Â ¿îµ¿°³½Ã 5-10ºÐÀü¿¡ Åõ¿©Çϸé Çù½ÉÁõÀ» ¿¹¹æÇÒ ¼ö ÀÖÀ½. 
* ÈíÀÔÇÏÁö ¸» °Í.     
      	
     | 
   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
   
    | ±Ý±â | 
       1) Áú»ê¿°Á¦Á¦¿¡ °ú¹ÎÁõ ¹× ±× º´·ÂÀÌ Àִ ȯÀÚ 
   2) µÎºÎ¿Ü»ó ¶Ç´Â ³úÃâÇ÷ ȯÀÚ(µÎ°³³»¾ÐÀ» »ó½Â½Ãų ¼ö ÀÖ´Ù.) 
   3) ÁßÁõÀÇ ºóÇ÷ȯÀÚ 
   4) ±Þ¼º ½É±Ù°æ»ö ȯÀÚ 
   5) ³ì³»Àå ȯÀÚ 
   6) ±Þ¼º ¼øÈ¯±â Àå¾Ö(¼îÅ©, ¼øÈ¯±â ¼îÅ©) 
   7) ÁßÁõÀÇ ÀúÇ÷¾Ð ȯÀÚ(¼öÃà±âÇ÷¾Ð 90mgHg ÀÌÇÏ) 
   8) ½ÉÀå¼îÅ©(´Ü, ÀûÀýÇÑ ±Ù¼öÃàÁ¦ Åõ¿©·Î ÁÂ½É½Ç È®Àå±â Ç÷¾ÐÀ» À¯ÁöÇÒ ½Ã¿¡´Â ¿¹¿Ü) 
   9) ½É¹ÚÃâ·®ÀÌ °¨¼ÒµÇ´Â ½É±Ù¼º Áúȯ(Æó»ö¼º ½É±Ù ºñ´ëÁõ) 
  10) ÇùÂø¼º ½É³¶¿° 
  11) ½ÉÀåÀÇ ±Þ¼º ¾Ð¹Ú 
  12) Æóµ¿¸Æ °íÇ÷¾Ð ȯÀÚ(°ü»óµ¿¸Æ ÁúȯÀÚ Æ÷ÇÔ) 
13) ÀÌ ¾àÀ» PDE-5 ÀúÇØÁ¦(¿¹: ¾Æ¹Ù³ªÇÊ, ½Çµ¥³ªÇÊ, ¹Ùµ¥³ªÇÊ, Ÿ´Ù¶óÇÊ, À¯µ¥³ªÇÊ, ¹Ì·Îµ¥³ªÇÊ µî)¿Í sGC ÀÚ±ØÁ¦(soluble Guanylate Cyclase Stimulator)(¿¹: ¸®¿À½Ã±¸¾Ñ µî)¸¦ »ç¿ë ÁßÀΠȯÀÚ¿¡°Ô Åõ¿©Çؼ´Â ¾È µÈ´Ù.
  | 
   
  
  
  
  
   
    | ½ÅÁßÅõ¿© | 
       1) ÀúÇ÷¾Ð ȯÀÚ. 
   2) ´ëµ¿¸Æ, ½Â¸ð°ü ÇùÂø. 
   3) °íÇ÷¾ÐÀ¸·Î ÀÎÇÑ ¼øÈ¯Á¶Àý Àå¾Ö(±â¸³¼º ¼øÈ¯Àå¾Ö).
 
  | 
   
  
    
  
  
  
  
  
   
    | ÀÌ»ó¹ÝÀÀ | 
    
         1) ¼øÈ¯±â°è : ºóÇ÷, Ç÷¾Ð°ÇÏ, ¿°¨, È«Á¶, ½É°èÇ×Áø, ±â¸³¼º ÀúÇ÷¾Ð, µå¹°°Ô ¾îÁö·¯¿ò µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. ¶ÇÇÑ °æ¿ì¿¡ µû¶ó ½ÉÀå¹Úµ¿ÀÇ ¼¸ÆÇö»ó°ú Çù½ÉÁõÀ¸·Î ÀÎÇÑ ÇãÅ»»óŰ¡ °üÂûµÇ´Â °æ¿ìµµ ÀÖÀ½. 
   2) Á¤½Å½Å°æ°è : µÎÅë, Çã¾à, µå¹°°Ô ½Ç½Å µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. 
   3) ¼Òȱâ°è : ±¸¿ª, ±¸Åä µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. 
   4) ±âŸ : µå¹°°Ô ¹ßÇÑ, ¿ä½Ç±Ý, º¯½Ç±Ý, ¾Ë·¯Áö¼º ÇǺιÝÀÀ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
  
   5) ±¹¿Ü ½ÃÆÇ ÈÄ Á¶»ç 
ÀÌ ¾à°ú ´Ù¸¥ ´ÏÆ®·Î±Û¸®¼¼¸° Á¦Á¦ÀÇ ½ÃÆÇ ÈÄ ¾Ë·ÁÁø ÀÌ»ó¹ÝÀÀÀº ´ÙÀ½°ú °°À¸¸ç Àڹߺ¸°í¿¡ ÀÇÇÑ °ÍÀ¸·Î ºóµµ¿Í ¾à¹°°£ÀÇ °ü°è¸¦ ÀÔÁõÇÒ ¼ö ¾ø´Ù.  
 - ½Å°æ°è : Çã¾à, Á¹¸²  
 - ÇǺΠ: ÇǺΠÇ÷°üÈ®Àå, È«Á¶, ¾à¹°¹ßÁø, ¹ÚÅ»ÇǺο° 
 - ¼Òȱâ°è : ±¸¿ª, ±¸Åä 
 - È£Èí±â°è : ÀϽÃÀû Àú»ê¼ÒÁõ  
 - ½ÉÇ÷°ü°è : ºó¸Æ
  
      
     | 
   
        
  
  
    
   
    | »óÈ£ÀÛ¿ë | 
       1) ´Ù¸¥ Áú»ê¿°Á¦Á¦, Ç÷¾Ð°ÇÏÁ¦, ¥â-Â÷´ÜÁ¦, Ä®½·±æÇ×Á¦, ½Å°æÀÌ¿ÏÁ¦, Ç׿ì¿ïÁõÁ¦Á¦, Æä³ëÄ¡¾ÆÁø°è ¾à¹° ¹× ¾ËÄڿðúÀÇ º´¿ëÅõ¿©·Î Ç÷¾Ð°ÇÏÀÛ¿ëÀÌ Áõ°µÉ ¼ö ÀÖ´Ù.
  
   2) ¿¡¸£°íŸ¹Î 
      ´ÏÆ®·Î±Û¸®¼¼¸°ÀÇ °æ±¸Åõ¿©´Â µðÈ÷µå·Î¿¡¸£°íŸ¹Î(dihydroergotamine)ÀÇ ÃÊȸ ´ë»ç¸¦ ÇöÀúÇÏ°Ô °¨¼Ò½Ã۰í, »ýüÀÌ¿ë·üÀ» Áõ°¡½ÃŲ´Ù. ¶ÇÇÑ, ¿¡¸£°íŸ¹ÎÀº Çù½ÉÁõÀ» ÃËÁøÇÏ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖÀ¸¹Ç·Î ´ÏÆ®·Î±Û¸®¼¼¸° ¼³ÇÏÁ¤À» 󹿹ÞÀº ȯÀÚ´Â ¿¡¸£°íŸ¹Î°è ¾à¹°°úÀÇ º´¿ëÀ» ÇÇÇÑ´Ù. ´Ù¸¸, º´¿ëÀÌ ºÒ°¡ÇÇÇÒ °æ¿ì ¸Æ°¢ Áßµ¶ÀÇ Áõ»óÀÌ ³ªÅ¸³ª´ÂÁö ¸é¹ÐÈ÷ °üÂûÇØ¾ß ÇÑ´Ù.
  
   3) ÇìÆÄ¸°°ú º»Á¦Á¦¸¦ ÇÔ²² »ç¿ëÇÒ ¶§¿¡´Â ÇìÆÄ¸°ÀÇ È¿°ú°¡ °¨¼ÒÇÑ´Ù.
  
   4) PDE-5 ÀúÇØÁ¦(Phosphodiesterase  type 5 inhibitor)¿Í sGC ÀÚ±ØÁ¦(soluble Guanylate Cyclase Stimulator) 
      ¨ç ÀÌ ¾àÀº PDE-5 ÀúÇØÁ¦(¿¹, ¾Æ¹Ù³ªÇÊ, ½Çµ¥³ªÇÊ, ¹Ù¸£µ¥³ªÇÊ, Ÿ´Ù¶óÇÊ µî)¿Í º´¿ëÇØ¼´Â ¾ÈµÈ´Ù. ÀÌ ¾à°ú º´¿ë ½Ã PDE-5 ÀúÇØÁ¦´Â À¯±â Áú»ê¿°Á¦Á¦ÀÇ ÀúÇ÷¾Ð È¿°ú¸¦ °È½ÃŲ´Ù. 
      ¨è ÀÌ ¾àÀº sGC ÀÚ±ØÁ¦ÀÎ ¸®¿À½Ã±¸¾Ñ°ú º´¿ëÇØ¼´Â ¾ÈµÈ´Ù. ÀÌ ¾à°ú º´¿ë ½Ã ÀúÇ÷¾ÐÀ» ¾ß±âÇÒ ¼ö ÀÖÀ¸¸ç ½Ã°£, ¿ë·® ÀÇÁ¸¼ºÀº ¿¬±¸µÇÁö ¾Ê¾Ò´Ù. ÁßÁõÀúÇ÷¾ÐÀÇ ÀûÀýÇÑ ÁöÁö¿ä¹ý¿¡ ´ëÇÑ ¿¬±¸´Â ¼öÇàµÇÁö ¾Ê¾ÒÁö¸¸, ¼Õ¹ß µé¾î¿Ã¸² ¹× Á᫐ ¿ëÀû È®´ë(central volume expansion) óġ¸¦ ÇÏ´Â °ÍÀÌ ÀûÀýÇÏ´Ù.(¡®9. °ú·®Åõ¿©½ÃÀÇ Ã³Ä¡¡¯ Ç× ÂüÁ¶)
  
4) PDE-5 ÀúÇØÁ¦(Phosphodiesterase type 5 inhibitor)¿Í sGC ÀÚ±ØÁ¦(soluble Guanylate Cyclase Stimulator) 
¨ç ÀÌ ¾àÀº PDE-5 ÀúÇØÁ¦(¿¹, ¾Æ¹Ù³ªÇÊ, ½Çµ¥³ªÇÊ, ¹Ù¸£µ¥³ªÇÊ, Ÿ´Ù¶óÇÊ, À¯µ¥³ªÇÊ, ¹Ì·Îµ¥³ªÇÊ µî)¿Í º´¿ëÇØ¼´Â ¾ÈµÈ´Ù. ÀÌ ¾à°ú º´¿ë ½Ã PDE-5 ÀúÇØÁ¦´Â À¯±â Áú»ê¿°Á¦Á¦ÀÇ ÀúÇ÷¾Ð È¿°ú¸¦ °È½ÃŲ´Ù. 
¨è ÀÌ ¾àÀº sGC ÀÚ±ØÁ¦(¿¹: ¸®¿À½Ã±¸¾Ñ µî)°ú º´¿ëÇØ¼´Â ¾ÈµÈ´Ù. ÀÌ ¾à°ú º´¿ë ½Ã ÀúÇ÷¾ÐÀ» ¾ß±âÇÒ ¼ö ÀÖ´Ù. 
¨é ÀÌ·¯ÇÑ »óÈ£ÀÛ¿ë¿¡ ´ëÇÑ ½Ã°£, ¿ë·® ÀÇÁ¸¼ºÀº ¿¬±¸µÇÁö ¾Ê¾ÒÀ¸¹Ç·Î ¼öÀÏ À̳»·Î º´¿ë Åõ¿©ÇÏ´Â °ÍÀº ±ÇÀåÇÏÁö ¾Ê´Â´Ù. ÁßÁõÀúÇ÷¾ÐÀÇ ÀûÀýÇÑ ÁöÁö¿ä¹ý¿¡ ´ëÇÑ ¿¬±¸´Â ¼öÇàµÇÁö ¾Ê¾ÒÁö¸¸, ¼Õ¹ß µé¾î¿Ã¸² ¹× Á᫐ ¿ëÀû È®´ë(central volume expansion) óġ¸¦ ÇÏ´Â °ÍÀÌ ÀûÀýÇÏ´Ù.(¡®9. °ú·®Åõ¿©½ÃÀÇ Ã³Ä¡¡¯ Ç× ÂüÁ¶) 
 | 
   
  
    
  
  
       	
  
  
   
    | Off-label Usage | 
    
      
	[Á¶È¸]    
     | 
   
     
  
  
  
  
  
   
    | Related FDA Approved Drug | 
    
       
     | 
      
  
  
  |  
     
   
  
    
       |  
      
        
          
            
                | Á¤º¸¿ä¾à |         
             
           
         | 
             	    
       |  
      | 
  
    µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
    
  
  
    
  
   |  
     
   
  
    
       |  
      
        
          
            
                | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |         
             
           
         | 
             	    
       |  
      | 	 |  
     
   
  
    
       |  
      
        
          
            
                | Á¦Ç°Á¤º¸ |            
             
           
         | 
             	  
       |  
      
  
    | Ç׸ñ | 
    ³»¿ë | 
   
  
  
   
    û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× | 
    
      
      
        
        685800141  
	    
	    
          [º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸] 
          
        
        
        
          
          
            \11,368 ¿ø/14.4mL/º´(2024.07.01)(Ãֽžడ)
            \11,372 ¿ø/14.4mL/º´(2022.01.01)(º¯°æÀü¾à°¡)
        
          
            
	 
  	   
  	   
       
      
       
       
     
      
      
     
      
    
    
      
     [»óº´ÄÚµåÁ¶È¸]
      
     [Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
    
     | 
   
  
  
   
    | Á¦Ç°¼º»ó | 
    
      ¹«»ö ³»Áö ¾à°£ ³ë¶õ»öÀÇ ¹æÇ⼺ ³¿»õ¸¦ °¡Áø ¸¼Àº ¾×ÀÌ ÃæÀüµÈ ÆßÇÁ½Ä½ºÇÁ·¹À̸¦ ÀåÂøÇÑ Åõ¸í À¯¸®º´  
      
	  [Á¦ÇüÁ¤º¸ È®ÀÎ]
     |   
   
  
  
  
  
  
   
    | ´ëü°ü·Ã | 
    ´ëÁ¶¾à | 
                                    
  
  
  
  
  
  
  
  
  
   
    | Æ÷À塤À¯Åë´ÜÀ§ | 
    1º´/»óÀÚ[(13.2g(14.4mL)/ ½ºÇÁ·¹ÀÌ ÀåÂøº´)] | 
   
  
  
  
   
    | º¸°ü¹æ¹ý | 
    ¹ÐºÀ¿ë±â, 25¡ÉÀÌÇÏ º¸°ü | 
   
  
  
                                                          															
  
  
  
  
  
       
  
  
  
   
  |  
     
   
  
    
       |  
      
        
          
            
                | º¹¾àÁ¤º¸ |            
             
           
         | 
             	  
       |  
      
  
    | Ç׸ñ | 
    ³»¿ë | 
   
   
    | LACTmed ¹Ù·Î°¡±â | 
    
      
        [¹Ù·Î°¡±â]
     | 
     
  
  
   
    | ¾à¸®ÀÛ¿ë | 
    
       
      À¯·áÁ¤º¸ÀÔ´Ï´Ù.
       
     | 
     
  
  
  
   
    | Ãà¾àº¹¾àÁöµµ | 
    
     
    À¯·áÁ¤º¸ÀÔ´Ï´Ù.
    
     | 
   
       
  
  
   
    | º¹¾àÁöµµ | 
    
     
    À¯·áÁ¤º¸ÀÔ´Ï´Ù.
    
     | 
   
                                                          															
  
   
  
  
   
    | ÀӺο¡´ëÇÑÅõ¿© | 
    
      
      
        
	      
	      
	        | *  | 
	        
	          ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù. 
	         | 
	         
	       
	       | 
	   
	  
	    |   | 
	   
	  
	    
	      FDA : Cµî±Þ 
				        	
					  
					
	   | 
	  
	  
	  
	     
	     
	     
	     
	     
	     
	   | 
	 
	
	  
	      
	      
	        | *  | 
	        
	          »ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
	         | 
	         
	      
	        | *  | 
	        
	          ¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
	         | 
	         
	       
	   | 
	 
       
     | 
   
  
  
  	   
  
  	   
  
  	   
  
  
     
      | Pharmacokinetics | 
      
       
      À¯·áÁ¤º¸ÀÔ´Ï´Ù.
      
       |   
     
  
  
  
  
  
  
  	
  
  
  
   
    | º¹¾à¶óº§ | 
    
    
    
      | À̹ÌÁö | 
      º¹¾à¼³¸í | 
     
    
    
        | 
      ¾îÁö·¯¿òÀÌ ÀÖÀ»¼ö ÀÖ½À´Ï´Ù. | 
     
    
       | 
     
    
     |  
    
      
	
	  
            | *  | 
	    º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. | 
	   
	  
            | *  | 
	    º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. | 
	   
	  
            | *  | 
	    ±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. | 
	   
	   
     |   
     | 
   
  	
  
  
   
    | Á¦Çüº° º¹¾àÁöµµ | 
    [±¸°¿ë½ºÇÁ·¹ÀÌ] | 
   
  
  
   
    | º¸°ü»ó ÁÖÀÇ | 
    
      
    	
     | 
   
  
  
   
    | Á¶Á¦½Ã ÁÖÀÇ | 
    
      
    	
     | 
      
 
 |  
     
   
  
    
       |  
      
        
          
            
                | ½É»çÁ¤º¸ |            
             
           
         | 
             	  
       |  
       |  
     
     
  
    
       |  
      
        
          
            
                | ÇмúÁ¤º¸ |          
             
           
         | 
             	  
       |  
      
  
    | Ç׸ñ | 
    ³»¿ë | 
   
  
    | DUR (ÀǾàǰ»ç¿ëÆò°¡) | 
    º´¿ë±Ý±â :
     
	 °í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
	 
	  [»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]										
	  ¿¬·É´ë±Ý±â :
      °í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
      
       [¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
       
       
        
        
     | 
   
  
   
    | µ¶¼ºÁ¤º¸ | 
    Glycerin¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â 
Nitroglycerin¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â 
  Ãâó: ±¹¸³µ¶¼º°úÇпø µ¶¼º¹°ÁúÁ¤º¸DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do  | 
   
  
   
    | Mechanism of Action | 
    
       Nitroglycerin¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Similar to other nitrites and organic nitrates, nitroglycerin is converted to nitric oxide (NO), an active intermediate compound which activates the enzyme guanylate cyclase. This stimulates the synthesis of cyclic guanosine 3',5'-monophosphate (cGMP) which then activates a series of protein kinase-dependent phosphorylations in the smooth muscle cells, eventually resulting in the dephosphorylation of the myosin light chain of the smooth muscle fiber. The subsequent release of calcium ions results in the relaxation of the smooth muscle cells and vasodilation. 
     | 
   
  
   
    | Pharmacology | 
     
       Nitroglycerin¿¡ ´ëÇÑ Pharmacology Á¤º¸ Nitroglycerin, an organic nitrate, is available in many forms as a vasodilator. Nitroglycerin is used in the treatement of angina pectoris and perioperative hypertension, to produce controlled hypotension during surgical procedures, to treat hypertensive emergencies, and to treat congestive heart failure associated with myocardial infarction. 
     | 
   
  
   
    | Metabolism | 
    
       Nitroglycerin¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Not Available 
     | 
   
  
   
    | Protein Binding | 
    
       Nitroglycerin¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ Not Available 
     | 
   
  
   
    | Half-life | 
    
       Nitroglycerin¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 3 minutes 
     | 
   
  
   
    | Absorption | 
    
       Nitroglycerin¿¡ ´ëÇÑ Absorption Á¤º¸ Not Available 
     | 
   
  
   
    | Pharmacokinetics | 
    
       NitroglycerinÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á 
	- ÀÛ¿ë¹ßÇö½Ã°£ ¹× ÀÛ¿ëÁö¼Ó½Ã°£ :  Á¦Çü¿¡ µû¶ó ´Ù¸§
 
 
  
  
	 - ´Ü¹é°áÇÕ : 60%
	
 - ´ë»ç : ÃÊȸÅë°úÈ¿°ú Å
	
 - ¹Ý°¨±â : 1-4ºÐ
	
 - ¼Ò½Ç : ´¢¸¦ ÅëÇØ ºñȰ¼ºÇü ´ë»çü·Î ¹è¼³
  
     | 
   
  
   
    | Biotransformation | 
    
       Nitroglycerin¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic, cytochrome P450 (P450) is a key enzyme of organic nitrate biotransformation 
     | 
   
  
   
    | Toxicity | 
    
       Nitroglycerin¿¡ ´ëÇÑ Toxicity Á¤º¸ Increased intracranial pressure, with any or all of persistent throbbing headache, confusion, and moderate fever; Vertigo; Palpitations; Visual disturbances; Nausea and vomiting (possibly with colic and even bloody diarrhea); Syncope (especially in the upright posture); Air hunger and dyspnea, later followed by reduced ventilatory effort; Diaphoresis, with the skin either flushed or cold and clammy; Heart block and bradycardia; Paralysis; Coma; Seizures; Death. 
     | 
   
  
   
    | Drug Interactions | 
    
       Nitroglycerin¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Alteplase	IV nitroglycerin decreases the effect of alteplaseDihydroergotamine	Possible antagonism of actionDihydroergotoxine	Possible antagonism of actionErgonovine	Possible antagonism of actionErgotamine	Possible antagonism of actionMethylergonovine	Possible antagonism of actionMethysergide	Possible antagonism of actionSildenafil	Possible significant hypotension with this combinationTadalafil	Possible significant hypotension with this combinationVardenafil	Possible significant hypotension with this combination 
     | 
   
  
   
    CYP450  Drug Interaction | 
    
      [CYP450 TableÁ÷Á¢Á¶È¸] 
     | 
   
  
   
    | Food Interaction | 
    
       Nitroglycerin¿¡ ´ëÇÑ Food Interaction Á¤º¸ Avoid alcohol.Take on empty stomach: 1 hour before or 2 hours after meals.Dissolve under the tongue. 
     | 
   
  
   
    | Drug Target | 
    
      
      [Drug Target]
     | 
   
  
   
    | Description | 
    
       Nitroglycerin¿¡ ´ëÇÑ Description Á¤º¸ A volatile vasodilator which relieves angina pectoris by stimulating guanylate cyclase and lowering cytosolic calcium. [PubChem] 
     | 
   
  
   
    | Drug Category | 
    
       Nitroglycerin¿¡ ´ëÇÑ Drug_Category Á¤º¸ Explosive AgentsNitrates and NitritesTocolytic AgentsVasodilator Agents 
     | 
   
  
   
    | Smiles String Canonical | 
    
       Nitroglycerin¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ [O-][N+](=O)OCC(CO[N+]([O-])=O)O[N+]([O-])=O 
     | 
   
  
   
    | Smiles String Isomeric | 
    
       Nitroglycerin¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ [O-][N+](=O)OCC(CO[N+]([O-])=O)O[N+]([O-])=O 
     | 
   
  
   
    | InChI Identifier | 
    
       Nitroglycerin¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C3H5N3O9/c7-4(8)13-1-3(15-6(11)12)2-14-5(9)10/h3H,1-2H2 
     | 
   
  
   
    | Chemical IUPAC Name | 
    
       Nitroglycerin¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 1,3-dinitrooxypropan-2-yl nitrate 
     | 
   
    
  |  
     
     
  
    
       |  
      
        
          
            
                | »ç¿ëÀÚÄÁÅÙÃ÷ |           
             
           
         | 
             	  
       |  
       |  
     
         
 
     | 
   
   
     | 
   
  
    
      
        
          
            
              - 
                ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2023-04-30
              
 
              - 
                
                 º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
                
              
     
             
         |                 
       
     |       
          
                
                    
                       ¾Ë¸² | 
                       
                      »ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù.  | 
                    
                    | 
               
      
      
                
                    
                       °æ°í | 
                     
                      µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù. 
                          Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â 
                          Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
                            ¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
                          ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
 | 
  
                    | 
               
  
 
  
    ¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é 
    ¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
   
  
 
  º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
 
  
  |  
                           
                         | 
                       
                      | 
                   |